Method and kit for detecting bacterial infection

US10094833B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10094833-B2
Application numberUS-201515502711-A
CountryUS
Kind codeB2
Filing dateAug 6, 2015
Priority dateAug 8, 2014
Publication dateOct 9, 2018
Grant dateOct 9, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to a novel antibody which binds to C-SLPI selected from the group consisting of SEQ ID NOs: 3 and 4.

First claim

Opening claim text (preview).

We claim: 1. An immunogen comprising a polypeptide hapten of 5-12 amino acids in length comprising the structure Gln-Cys-Leu-Arg (SEQ ID NO: 10), wherein the N-terminus region of the polypeptide hapten comprises SEQ ID NO: 10; and wherein the polypeptide hapten is linked to an immunogenicity conferring carrier molecule by the C-terminal amino acid of the polypeptide hapten. 2. An antibody, or antigen binding fragment thereof, that is capable of specifically binding, to an epitope of C-terminal peptide fragment of Secretory leukocyte protease inhibitor (C-SLPI), the peptide fragment which is 10, 11 or 12 amino acids in length and comprises SEQ ID NO: 6 wherein the N-terminus region of the polypeptide fragment comprises SEQ ID NO: 6 and wherein the cross-reactivity of the antibody with full-length SLPI is <0.05%. 3. A method of determining an individual's C-SLPI level by: (a) contacting an antibody specific for C-terminal fragment of Secretory leukocyte protease inhibitor (C-SLPI) with a sample from the individual; and (b) detecting the amount of C-terminal fragment of Secretory leukocyte protease inhibitor (C-SLPI) in the sample; wherein the cross-reactivity of the antibody with full-length Secretory leukocyte protease inhibitor (SLPI) is <0.05%.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10094833B2 cover?
The invention relates to a novel antibody which binds to C-SLPI selected from the group consisting of SEQ ID NOs: 3 and 4.
Who is the assignee on this patent?
Randox Laboratories Ltd
What technology area does this patent fall under?
Primary CPC classification G01N33/573. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).